Table 1.
Overview of HGSOC patients. International Federation of Gynecology and Obstetrics (FIGO) classification.
| Patient | Age | Grade | FIGO | Chemotherapy Regimen | BRCA1/2 Status |
|---|---|---|---|---|---|
| A | 56 | G3 | IV | Carboplatin auc 5 a + TXL 175 b + BEVA 15 c (3 cycles) | WT |
| B | 43 | G3 | IIIC | Carboplatin auc 5 + Caelyx 30 d (3 cycles) | mutBRCA1 class 5 |
| C | 46 | G3 | IIIC | Carboplatin auc 5 + TXL 80 (3 cycles) | WT |
| D | 69 | G3 | IIIC | Carboplatin auc 5 + TXL 175 (3 cycles) | WT |
| E | 55 | n.d. | IIIC | Carboplatin auc 3 + TXL 80 (cycles n.d.) | WT |
Grade 3: (high grade) poorly differentiated ovarian epithelial cancer cells. FIGO classification: IIIC: Tumor involves one or both ovaries with macroscopic (>2 cm) cytologically or histologically confirmed metastasis to the peritoneum outside the pelvis and/or to the retroperitoneal lymph nodes. IV: Distant metastasis excluding peritoneal metastasis. Includes hepatic parenchymal metastasis. a AUC: area under the curve, b TXL: paclitaxel 175 mg/m2, c BEVA: bevacizumab, d Caelyx: liposomal doxorubicin 30 mg/m2, WT: wild type, mutBRCA1: mutatedBRCA1.